Pilot randomized controlled trial of a program to enhance experience and adherence with adjuvant endocrine therapy among women with non-metastatic breast cancer: 12-month quantitative results.

Autor: Assan O; Faculty of Pharmacy, Université Laval, 1050 Avenue de la Médecine, Quebec, QC, G1V 0A6, Canada., Memoli V; Aix-Marseille University, INSERM, IRD, SESSTIM, ISSPAM, Cancer, Biomedicine & Society Group, Équipe Labellisée Ligue Contre Le Cancer, 27 bd Jean Moulin, 13385, Marseille, France., Guillaumie L; CHU de Québec-Université Laval Research Center, Population Health and Optimal Health Practices Axis, 1050 Chemin Ste-Foy, Quebec, QC, G1S 4L8, Canada.; Faculty of Nursing, Pavillon Ferdinand-Vandry, Université Laval, 1050 Avenue de la Médecine, Quebec, QC, G1V 0A6, Canada., Turcotte V; CHU de Québec-Université Laval Research Center, Population Health and Optimal Health Practices Axis, 1050 Chemin Ste-Foy, Quebec, QC, G1S 4L8, Canada., Lemay M; Centre des Maladies du Sein (Breast Disease Center), CHU de Québec-Université Laval, Hôpital du Saint-Sacrement, 1050 Chemin Ste-Foy, Quebec, QC, G1S 4L8, Canada., Dionne A; Faculty of Pharmacy, Université Laval, 1050 Avenue de la Médecine, Quebec, QC, G1V 0A6, Canada.; Centre des Maladies du Sein (Breast Disease Center), CHU de Québec-Université Laval, Hôpital du Saint-Sacrement, 1050 Chemin Ste-Foy, Quebec, QC, G1S 4L8, Canada.; CHU de Québec-Université Laval Research Center, Oncology Axis, 1050 Chemin Ste-Foy, Quebec, QC, G1S 4L8, Canada., Lemieux J; Centre des Maladies du Sein (Breast Disease Center), CHU de Québec-Université Laval, Hôpital du Saint-Sacrement, 1050 Chemin Ste-Foy, Quebec, QC, G1S 4L8, Canada.; CHU de Québec-Université Laval Research Center, Oncology Axis, 1050 Chemin Ste-Foy, Quebec, QC, G1S 4L8, Canada., Provencher L; Centre des Maladies du Sein (Breast Disease Center), CHU de Québec-Université Laval, Hôpital du Saint-Sacrement, 1050 Chemin Ste-Foy, Quebec, QC, G1S 4L8, Canada.; CHU de Québec-Université Laval Research Center, Oncology Axis, 1050 Chemin Ste-Foy, Quebec, QC, G1S 4L8, Canada., Gotay C; School of Population and Public Health, University of British Columbia, 2206 East Mall, Vancouver, BC, V6T 1Z3, Canada., de Bruin M; Radboud Institute for Health Sciences, IQ Healthcare, Nijmegen, the Netherlands., Guénette L; Faculty of Pharmacy, Université Laval, 1050 Avenue de la Médecine, Quebec, QC, G1V 0A6, Canada.; CHU de Québec-Université Laval Research Center, Population Health and Optimal Health Practices Axis, 1050 Chemin Ste-Foy, Quebec, QC, G1S 4L8, Canada., Lauzier S; Faculty of Pharmacy, Université Laval, 1050 Avenue de la Médecine, Quebec, QC, G1V 0A6, Canada. sophie.lauzier@pha.ulaval.ca.; CHU de Québec-Université Laval Research Center, Population Health and Optimal Health Practices Axis, 1050 Chemin Ste-Foy, Quebec, QC, G1S 4L8, Canada. sophie.lauzier@pha.ulaval.ca.; Équipe de Recherche Michel-Sarrazin en Oncologie Psychosociale et Soins Palliatifs (ERMOS), 2101 Chemin Saint-Louis, Quebec, QC, G1T 1P5, Canada. sophie.lauzier@pha.ulaval.ca.; Cancer Research Center, Pavillon Ferdinand-Vandry, Université Laval, 1050 Avenue de la Médecine, Quebec, QC, G1V 0A6, Canada. sophie.lauzier@pha.ulaval.ca.
Jazyk: angličtina
Zdroj: Journal of cancer survivorship : research and practice [J Cancer Surviv] 2024 May 04. Date of Electronic Publication: 2024 May 04.
DOI: 10.1007/s11764-024-01599-y
Abstrakt: Purpose: Adjuvant endocrine therapy (AET) reduces recurrence risk after hormone receptor-positive breast cancer, but non-adherence is common. We pilot-tested SOIE, a program to enhance AET experience and adherence, to assess its acceptability, feasibility, and effects on psychosocial precursors of AET adherence.
Methods: We conducted a 12-month pilot randomized controlled trial among women who had a first AET prescription. Intervention group received SOIE while control group received usual care. Psychosocial factors from the Theory of Planned Behavior (TPB) (intention - primary outcome -, attitude, subjective norm, behavioral control), additional constructs (AET knowledge, social support, coping planning), impact of AET services received, and adherence were measured by questionnaires at baseline, 3-month, and 12-month endpoints. Group patterns were compared using repeated measures analyses with generalized estimating equations.
Results: A total of 106 women were randomized (participation = 54.9%; intervention n = 52; control n = 54; retention = 93.8%). Among SOIE women, ≥ 90% received the program components and were satisfied. Both groups scored high on adherence intentions and group patterns over time were not statistically different. In the intervention group, AET knowledge and coping planning with side effects increased (group-by-time p-value = .002 and .016), a higher proportion reported that AET services received helped them take their AET (p < .05) and have a consistent daily intake (p = .01).
Conclusion: SOIE is feasible and acceptable for survivors with an AET. SOIE did not significantly impact adherence intentions but was beneficial for other program outcomes and daily intake.
Implications for Cancer Survivors: SOIE may represent an encouraging avenue to enhance supportive care and empower survivors with managing AET.
(© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: